TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14728104

Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5-20 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (healthy volunteers, n=10)
Number of subjects: 10
Study: 12564573

Group type: EXPERIMENTAL
Intervention: Intervention groups (specifics not provided)
Number of subjects: 1507

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1507
Study: 9701538

Group type: EXPERIMENTAL
Intervention: Full version of warning signs (with all components included)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Original version of warning signs (with components omitted)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Versions omitting hazard, consequences, and instructions statements
Number of subjects: 84
Study: 7536515

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 34
Study: 2914436

Group type: EXPERIMENTAL
Intervention: Epiquick patch test on the left side
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epiquick patch test on the right side
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Concordant reactions on both sides
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Negative reactions on the left side
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rechallenge after 6 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall reproducibility of positive reactions
Number of subjects: 100
Study: 770080

Group type: EXPERIMENTAL
Intervention: 1200 mg azapropazone daily
Number of subjects: 108

Group type: COMPARATOR
Intervention: 3.9 g aspirin daily
Number of subjects: 108
Study: 31375713

Group type: EXPERIMENTAL
Intervention: AR pseudocolor low vision aid
Number of subjects: 10
Study: 28326559

Group type: EXPERIMENTAL
Intervention: RG7652 (10, 40, 150, 300, 600, or 800 mg single dose)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: RG7652 (40 or 150 mg multiple doses once weekly for 4 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: RG7652 with atorvastatin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 26490026

Group type: EXPERIMENTAL
Intervention: Concurrent chemo-endocrine therapy (goserelin for premenopausal women or an aromatase inhibitor for postmenopausal women)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Chemotherapy alone (paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Concurrent therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 28
Study: 23266743

Group type: EXPERIMENTAL
Intervention: 6 tablets of dietary supplement (DS) containing red yeast rice extract, policosanol and artichoke leaf extract
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 3 tablets of dietary supplement (DS) containing red yeast rice extract, policosanol and artichoke leaf extract
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 6 tablets of dietary supplement (DS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 3 tablets of dietary supplement (DS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 6 tablets of dietary supplement (DS) and 3 tablets of dietary supplement (DS)
Number of subjects: 45
Study: 21469913

Group type: EXPERIMENTAL
Intervention: Earthing (contact with the Earth via a copper conductor)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (no contact with the Earth)
Number of subjects: 168
Study: 17428714

Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (40 or 80 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard incremental cycling exercise
Number of subjects: 9
Study: 17150167

Group type: EXPERIMENTAL
Intervention: Reflectance-mode confocal microscopy (RCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ivory soap at selected concentrations
Number of subjects: 0
Study: 12832710

Group type: EXPERIMENTAL
Intervention: Activated leucocytes co-cultured with fibroblast-like synoviocytes (FLS) from RA patients.
Number of subjects: 0
Study: 10683600

Group type: EXPERIMENTAL
Intervention: SPORT (dietary supplement)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Gelatin placebo
Number of subjects: 9
Study: 9587555

Group type: EXPERIMENTAL
Intervention: IFN alpha 2b 10 MIU TIW for 2 months, then 6 MIU TIW for 4 months (Group 1)
Number of subjects: 23

Group type: COMPARATOR
Intervention: IFN alpha 2b 6 MIU TIW for 6 months (Group 2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Group 2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 18 patients who had a second biopsy 6 months after therapy
Number of subjects: 23
Study: 8410127

Group type: EXPERIMENTAL
Intervention: 4HPR 200 mg/d for 5 years
Number of subjects: 0
Study: 30776254

Group type: EXPERIMENTAL
Intervention: Taurine (50 mg kg‐1)
Number of subjects: 11
Study: 30268158

Group type: EXPERIMENTAL
Intervention: Low-frequency electrostimulation (ES) administered via CarebandR wristband on unilateral PC6 acupoint
Number of subjects: 80

Group type: COMPARATOR
Intervention: Duloxetine or pregabalin (pharmacological management)
Number of subjects: 80
Study: 26672608

Group type: EXPERIMENTAL
Intervention: 25 mg elemental iron once weekly (Group-A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 mg elemental iron twice weekly (Group-B)
Number of subjects: 0
Study: 24511573

Group type: EXPERIMENTAL
Intervention: Male practitioners
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Female practitioners
Number of subjects: 199
Study: 22890091

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 264.2 mg b.i.d. for 5-14 days
Number of subjects: 267

Group type: COMPARATOR
Intervention: Levofloxacin 200 mg b.i.d. for 5-14 days
Number of subjects: 267
Study: 18030623

Group type: EXPERIMENTAL
Intervention: Current smoking rate among Chinese-American adults
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Recent immigrant men (<5 years in the U.S.)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: U.S.-born Chinese-American men
Number of subjects: 1054

Group type: COMPARATOR
Intervention: General Texas population
Number of subjects: 1054
Study: 18946341

Group type: EXPERIMENTAL
Intervention: Concentration-controlled MMF regimen (target exposure 45 mg hr/L)
Number of subjects: 901

Group type: COMPARATOR
Intervention: Fixed-dose MMF regimen
Number of subjects: 901
Study: 16054584

Group type: EXPERIMENTAL
Intervention: Amodiaquine + Artesunate (ADQ+ART) combination
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Artemether + Lumefantrine (Coartem) combination
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Sulphadoxine/Pyrimethamine (SP)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Chloroquine (CHQ)
Number of subjects: 168
Study: 12468602

Group type: EXPERIMENTAL
Intervention: Spread enriched with plant sterol-esters (12 g/100 g plant sterols), intake of 15 g/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control spread not fortified with plant sterol-esters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spread enriched with plant sterol-esters
Number of subjects: 0
Study: 10522000

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily before breakfast
Number of subjects: 160

Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily at bedtime
Number of subjects: 160
Study: 7491883

Group type: EXPERIMENTAL
Intervention: Preterm infant formula with vitamin A content of 820 IU/MJ
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Preterm infant formula with vitamin A content of 1640 IU/MJ
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Preterm infant formula with vitamin A content of 2900 IU/MJ
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Standard infant formulas with a vitamin A content of 715 IU/MJ
Number of subjects: 61
Study: 1826987

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (600 mg ascorbic acid, 300 mg alpha‐tocopherol, 27 mg beta‐carotene, and 75 micrograms selenium in yeast daily)
Number of subjects: 80
Study: 6130944

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: All four drugs
Number of subjects: 24
Study: 29999214

Group type: EXPERIMENTAL
Intervention: Tailored intervention with TPB components
Number of subjects: 130

Group type: COMPARATOR
Intervention: Tailored comparison group without TPB components
Number of subjects: 130

Group type: COMPARATOR
Intervention: Untailored comparison group with TPB components
Number of subjects: 130

Group type: COMPARATOR
Intervention: Comparison group with neither tailoring nor TPB components
Number of subjects: 130
Study: 28264177

Group type: EXPERIMENTAL
Intervention: Expert software named VoiceDiab (experimental group A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Manual method of meal‐bolus estimation (control group B)
Number of subjects: 12
Study: 25869393

Group type: EXPERIMENTAL
Intervention: Prucalopride
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 23664767

Group type: EXPERIMENTAL
Intervention: Heliox + PEP (n = 6)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oxygen + PEP (n = 6)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Heliox (n = 11)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oxygen without PEP (n = 9)
Number of subjects: 32
Study: 21893649

Group type: EXPERIMENTAL
Intervention: Daily controller use (yes)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Nonadherent controller use (yes)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Any controller use (yes)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Leukotriene inhibitors (yes)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (yes)
Number of subjects: 482
Study: 19646747

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond adhesive (PB), 24h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond adhesive (PB), 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scotchbond Multi‐Purpose (SBMP), 24h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scotchbond Multi‐Purpose (SBMP), 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SBMP etch and primer + Clearfil SE Bond adhesive (SE), 24h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SBMP etch and primer + Clearfil SE Bond adhesive (SE), 3 months
Number of subjects: 0
Study: 18042568

Group type: EXPERIMENTAL
Intervention: Information-theoretic approach applied to ophthalmologic trial data
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meta-analytic framework
Number of subjects: 0
Study: 15235319

Group type: EXPERIMENTAL
Intervention: DCA (50 mg·kg‐1 body mass in 50 mL saline)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (without DCA)
Number of subjects: 7
Study: 11238496

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg, 3 times daily for 4 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (3 times daily for 4 weeks)
Number of subjects: 48
Study: 9928576

Group type: COMPARATOR
Intervention: Paclitaxel after doxorubicin-cyclophosphamide (AC) in INT 0148 and NSABP B-28
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel after doxorubicin-cyclophosphamide (AC) in NSABP B-27
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential treatment A(doxorubicin)-T(paclitaxel)-C(cyclophosphamide) with G-CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: AC x 4 followed by high-dose chemotherapy with stem cell support
Number of subjects: 0
Study: 7886752

Group type: EXPERIMENTAL
Intervention: Bed nets impregnated with pyrethroid insecticide
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Vaccination against Japanese encephalitis
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study: 3346491

Group type: EXPERIMENTAL
Intervention: Nutrient analysis computer printouts with varying characteristics (type, amount, format)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Nutrient data only printouts
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Printouts including short messages listing sources and functions of nutrients
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Data presented in graphic format
Number of subjects: 553
Study: 31204870

Group type: EXPERIMENTAL
Intervention: Self-administered anonymous questionnaire regarding fertility management knowledge
Number of subjects: 2235

Group type: EXPERIMENTAL
Intervention: Education and public health campaigns about contraceptive options and age-related fertility decline
Number of subjects: 2235
Study: 27959700

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Platinum therapy plus pemetrexed (500 mg/m² + carboplatin AUC5 or cisplatin 75 mg/m² every 3 weeks)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 419

Group type: COMPARATOR
Intervention: Platinum therapy plus pemetrexed
Number of subjects: 419
Study: 26041765

Group type: EXPERIMENTAL
Intervention: Hematologic specialists
Number of subjects: 240

Group type: COMPARATOR
Intervention: Hematologic specialty
Number of subjects: 240

Group type: COMPARATOR
Intervention: Comfort level with prescribing treatment to ECOG 4 patients
Number of subjects: 240
Study: 23748156

Group type: EXPERIMENTAL
Intervention: COPE TEEN program
Number of subjects: 779

Group type: COMPARATOR
Intervention: Attention control program
Number of subjects: 779
Study: 21494196

Group type: EXPERIMENTAL
Intervention: Real electroacupuncture treatment
Number of subjects: 124

Group type: COMPARATOR
Intervention: Simulated electroacupuncture treatment (Control)
Number of subjects: 124
Study: 19688181

Group type: EXPERIMENTAL
Intervention: Tacrolimus (3 mg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 16135780

Group type: EXPERIMENTAL
Intervention: Turner syndrome group during easy (two‐operand) arithmetic task
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Turner syndrome group during difficult (three‐operand) arithmetic task
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Turner syndrome group performance on both math tasks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Typically developing controls during easy (two‐operand) arithmetic task
Number of subjects: 30

Group type: COMPARATOR
Intervention: Typically developing controls during difficult (three‐operand) arithmetic task
Number of subjects: 30
Study: 15356433

Group type: EXPERIMENTAL
Intervention: Daily needle aspiration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical lavage
Number of subjects: 0
Study: 11728081

Group type: EXPERIMENTAL
Intervention: Early active training program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional less active training program
Number of subjects: 50
Study: 9133750

Group type: EXPERIMENTAL
Intervention: Imipramine 150 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active treatments (Imipramine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discriminative centers (DC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-discriminative centers (NDC)
Number of subjects: 0
Study: 8434321

Group type: EXPERIMENTAL
Intervention: Microscopic removal of lumbar disc herniation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard procedure for lumbar disc herniation
Number of subjects: 60
Study: 3538156

Group type: EXPERIMENTAL
Intervention: Hexabrix (ioxaglate meglumine and ioxaglate sodium)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Renografin‐60 (diatrizoate meglumine and diatrizoate sodium)
Number of subjects: 60
Study: 31861918

Group type: EXPERIMENTAL
Intervention: Comprehensive training intervention (11-hour training including a health literacy lecture and five interactive small-group sessions)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Comprehensive training intervention
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Demonstrated skills in videotaped consultations (subsample)
Number of subjects: 79
Study: 27884979

Group type: EXPERIMENTAL
Intervention: Behavior Activation (BA)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Supportive Therapy (ST)
Number of subjects: 206
Study: 27083332

Group type: EXPERIMENTAL
Intervention: Ponatinib (45 mg once daily)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Imatinib (400 mg once daily)
Number of subjects: 307
Study: 25092938

Group type: EXPERIMENTAL
Intervention: Personal Health Partner (PHP)
Number of subjects: 0
Study: 22801381

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 200

Group type: COMPARATOR
Intervention: Clamp and tie (CT)
Number of subjects: 200
Study: 19269800

Group type: EXPERIMENTAL
Intervention: High PEEP
Number of subjects: 2447

Group type: COMPARATOR
Intervention: Low PEEP
Number of subjects: 2447
Study: 17478211

Group type: EXPERIMENTAL
Intervention: ACE stimulation rate
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Higher rate ACE RE stimulation rate
Number of subjects: 71
Study: 14760148

Group type: COMPARATOR
Intervention: 400 microg salbutamol administered through a pMDI+spacer 20 minutes before induction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1500 microg nebulised salbutamol inhaled throughout the induction procedure
Number of subjects: 20
Study: 12091753

Group type: EXPERIMENTAL
Intervention: Low-fat diet (phase I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Moderate-fat diet (calorie-controlled, phase II)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Moderate-fat diet (MF)
Number of subjects: 100
Study: 10094739

Group type: EXPERIMENTAL
Intervention: Giant prosthetic reinforcement of the visceral sac (GPRVS)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Laparoscopic transabdominal preperitoneal repair (TAPP)
Number of subjects: 79
Study: 7583013

Group type: EXPERIMENTAL
Intervention: Garlic capsules
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 10
Study: 2378856

Group type: EXPERIMENTAL
Intervention: Topical timolol maleate (0.5%)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Topical betaxolol hydrochloride (0.5%)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study: 387069

Group type: EXPERIMENTAL
Intervention: 4 mg of micronized 17 beta‐oestradiol and 3 mg norethisterone (Netagen 403)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: 4 mg 17 beta‐oestradiol plus 2 mg of oestriol and 3 mg norethisterone (Netagen 423)
Number of subjects: 215

Group type: COMPARATOR
Intervention: 50 microgram ethinyl oestradiol and 3 mg norethisterone (Netasyn)
Number of subjects: 215
Study: 31220476

Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 62

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 62
Study: 28572418

Group type: EXPERIMENTAL
Intervention: EAT evidence-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25934168

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20-minute session at 2 mA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cathodal tDCS (20-minute session at 2 mA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham tDCS (20-minute session)
Number of subjects: 36
Study: 24147745

Group type: COMPARATOR
Intervention: gel without desensitizing agent (n=17)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: gel with 2% sodium fluoride (n=17)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: gel with 10% CPP‐ACP (n=17)
Number of subjects: 51
Study: 22336530

Group type: EXPERIMENTAL
Intervention: Early use of imipenem/cilastatin plus vancomycin with subsequent de-escalation (DE)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Conventional antimicrobial treatment (non-de-escalation, NDE)
Number of subjects: 109
Study: 19047297

Group type: EXPERIMENTAL
Intervention: Adjuvant goserelin after radiation therapy (RT)
Number of subjects: 945

Group type: COMPARATOR
Intervention: RT alone (no adjuvant goserelin)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Adjuvant goserelin
Number of subjects: 945

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 945
Study: 16978673

Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine/pyrimethamine (AQ+SP)
Number of subjects: 4472
Study: 15362414

Group type: EXPERIMENTAL
Intervention: Moderate exercise program for 10 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: No-exercise control group
Number of subjects: 64
Study: 11408151

Group type: EXPERIMENTAL
Intervention: Loperamide-simethicone combination formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Loperamide alone
Number of subjects: 12
Study: 9739365

Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound examination
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Healthy contralateral ankle
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 34
Study: 8290188

Group type: EXPERIMENTAL
Intervention: 100 micrograms misoprostol
Number of subjects: 63

Group type: COMPARATOR
Intervention: 3 mg dinoprostone
Number of subjects: 63
Study: 2163253

Group type: EXPERIMENTAL
Intervention: Soy cotyledon fiber supplementation (15 grams per day in three divided doses)
Number of subjects: 20
Study: 892352

Group type: EXPERIMENTAL
Intervention: Salt and water restriction plus diuretics
Number of subjects: 43

Group type: COMPARATOR
Intervention: Salt and water restriction alone
Number of subjects: 43
Study: 30829779

Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum (CCH) 0.84 mg
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 29061556

Group type: EXPERIMENTAL
Intervention: Automated and personal reminder (audio reminder and support calls)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 169
Study: 24861902

Group type: EXPERIMENTAL
Intervention: 200 mg oral caffeine intake
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 36